ALDR - Alder BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.58B
Enterprise Value 3
1.47B
Trailing P/E
N/A
Forward P/E 1
-6.72
PEG Ratio (5 yr expected) 1
-0.20
Price/Sales (ttm)
N/A
Price/Book (mrq)
14.31
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-4.46

Trading Information

Stock Price History

Beta (3Y Monthly) 2.95
52-Week Change 340.19%
S&P500 52-Week Change 37.98%
52 Week High 318.99
52 Week Low 38.39
50-Day Moving Average 314.79
200-Day Moving Average 312.26

Share Statistics

Avg Vol (3 month) 32.74M
Avg Vol (10 day) 34.24M
Shares Outstanding 583.64M
Float 70.43M
% Held by Insiders 15.20%
% Held by Institutions 1101.40%
Shares Short (Sep 30, 2019) 412.05M
Short Ratio (Sep 30, 2019) 42.19
Short % of Float (Sep 30, 2019) 419.51%
Short % of Shares Outstanding (Sep 30, 2019) 414.41%
Shares Short (prior month Aug 30, 2019) 416.04M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-40.94%
Return on Equity (ttm)-113.83%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-161.99M
EBITDA -329.07M
Net Income Avi to Common (ttm)-322.8M
Diluted EPS (ttm)-4.40
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)409.31M
Total Cash Per Share (mrq)4.89
Total Debt (mrq)193.36M
Total Debt/Equity (mrq)89.17
Current Ratio (mrq)8.94
Book Value Per Share (mrq)1.32

Cash Flow Statement

Operating Cash Flow (ttm)-258.2M
Levered Free Cash Flow (ttm)-188.19M